주요상품

Biocare Medical Key Antibodies for Breast cancers 2017-05-18 16:07:53

upload image
upload image
 
Breast cancers are the 1st most diagnosed cancer in the United States, with about 14% of new cancer cases classified as breast and contributing 6.9% of cancer deaths yearly. As of 2012, there were approximately 3,000,000 women living with breast cancer in the United States. Those diagnosed with breast cancer have a 5 year survival rate of 89.4%. Over the last 10 years, the new breast cancer case rate has been stable, while the death rate has dropped 1.9% per year. Biocare Medical is proud to offer key breast antibodies that may aid in the identification of their respective proteins by IHC in FFPE tissues.
SEER Cancer Statistics Factsheets: Breast Cancer. National Cancer Institute. Bethesda, MD,http://seer.cancer.gov/statfacts/html/breast.html
Key Antibodies for Breast Cancer
 
Key Antibodies for Breast Cancer
upload image
 
Key Antibodies for Breast Cancer
 
upload image
CK5/14 + p63 + CK7/18
This multiplex complements morphologicalevaluation of breast lesions, due to thedifferential expression of the luminal (CK7/8)vs. basal and myoepithelial markers (CK5/14,p63). Use of these antibodies has been shown to significantly increase diagnostic inter-observer agreement among pathologists.
 
upload image
GCDFP-15 + Mammaglobin
Mammaglobin is reported to be a more sensitive marker than GCDFP-15 for breast carcinoma; however, it lacks the pecificity of GCDFP-15. The combination of the two markers may help to establish the correct interpretation of metastatic breast carcinoma.
 
 
upload image
p120 + E-cadherin
Studies have shown accurate categorization of ductal vs. lobular neoplasia in the breast with p120 Catenin + E-cadherin. It can also aid in further clarification in the separation of low-grade ductal carcinoma in situ from lobular neoplasia.
 
 
upload image
Estrogen Receptor (ER) [SP1]
ER is present in the nuclei of epithelial cells in normal breast and endometrial tissues, as well as a subset of breast carcinomas. The SP1 clone has been shown to have higher sensitivity than mouse monoclonals in breast cancer.
 
 
 
 
upload image
Progesterone Receptor (PR) [16]
PR content of breast cancer tissue is an important parameter in the prediction of prognosis and response to endocrine therapy. The PR [16] is directed against the human PR molecule and recognizes both the A- andB- forms of human progesterone receptor.
 
upload image
GATA-3
The expression of GATA-3 has a strong association with estrogen receptor-alpha expression in breast cancer. Evidence exists that GATA-3 may be used to predict response to hormonal therapy of breast cancer patients.
 
 
 
upload image
Cytokeratin 7 (CK7)
Cytokeratin 7 is expressed in epithelial cells of ovary, lung and breast. It is often used in conjunction with Cytokeratin 20 and CDX-2 to aid in distinguishing pulmonary, ovarian
and breast carcinomas (CK7+) from most colon carcinomas (CK7-)
upload image
PD-1
Programmed death 1 (PD-1) is expressed on the cell surface of activated T- and B-cells. The presence of PD-1 positive tumor-infiltrating lymphocytes (TIL) has been associated with poor prognosis in human breast cancers and may be useful in antibody therapy targeting the PD-1/PD-L1 signaling pathway.
upload image
c-erbB-2/HER2
The c-erbB-2 protein is over-expressed in a variety of carcinomas, especially breast and ovary. Studies show that c-erbB-2 positive breast
cancer usually correlates with negative staining for ER and PR, indicating a poorer predictive outcome with positive c-erbB-2 staining.
 
                                                        upload image
 
upload image
목록보기
최근본상품 TOP